Multitargeted Opioid Ligand Discovery as a Strategy to Retain Analgesia and Reduce Opioid-Related Adverse Effects

• Published in: Journal of medicinal chemistry Vol. 66; no. 6; pp. 3746 - 3784
• Main Authors: Smith, Maree T., Kong, Dehui, Kuo, Andy, Imam, Mohammad Z., Williams, Craig M.
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 23.03.2023
• Subjects: Analgesia; Analgesics, Opioid - adverse effects; Animals; Ligands; Morphine; Pain - drug therapy; Receptors, Opioid, delta; Receptors, Opioid, mu
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.2c01695

The global “opioid crisis” has placed enormous pressure on the opioid ligand discovery community to produce novel opioid analgesics with superior opioid-related adverse-effect profiles compared with morphine. In this Perspective, the multitargeted opioid ligand strategy for the discovery of opioid analgesics with superior preclinical therapeutic indices relative to morphine is reviewed and discussed. Dual-targeted μ-opioid (MOP)/δ-opioid (DOP) ligands in which the in vitro DOP antagonist potency at least equals that of the MOP agonist activity, and are devoid of DOP or κ-opioid (KOP) agonist activity, are sufficiently promising candidates to warrant further investigation. Dual-targeted MOP/NOP partial agonists have superior preclinical therapeutic indices to morphine and/or fentanyl in nonhuman primates and are also considered promising. Based on the poor preclinical and clinical therapeutic indices of cebranopadol, which is a full agonist at MOP, DOP, and NOP receptors and a partial agonist at the KOP receptor, this pharmacologic template should be avoided.